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Abstract
Background: Gamma-linolenic acid is a known inhibitor of tumour cell proliferation and migration
in both in vitro and  in vivo conditions. The aim of the present study was to determine the
mechanisms by which gamma-linolenic acid (GLA) osmotic pump infusion alters glioma cell
proliferation, and whether it affects cell cycle control and angiogenesis in the C6 glioma in vivo.
Methods: Established C6 rat gliomas were treated for 14 days with 5 mM GLA in CSF or CSF
alone. Tumour size was estimated, microvessel density (MVD) counted and protein and mRNA
expression measured by immunohistochemistry, western blotting and RT-PCR.
Results: GLA caused a significant decrease in tumour size (75 ± 8.8%) and reduced MVD by 44 ±
5.4%. These changes were associated with reduced expression of vascular endothelial growth
factor (VEGF) (71 ± 16%) and the VEGF receptor Flt1 (57 ± 5.8%) but not Flk1. Expression of
ERK1/2 was also reduced by 27 ± 7.7% and 31 ± 8.7% respectively. mRNA expression of matrix
metalloproteinase-2 (MMP2) was reduced by 35 ± 6.8% and zymography showed MMP2 proteolytic
activity was reduced by 32 ± 8.5%. GLA altered the expression of several proteins involved in cell
cycle control. pRb protein expression was decreased (62 ± 18%) while E2F1 remained unchanged.
Cyclin D1 protein expression was increased by 42 ± 12% in the presence of GLA. The cyclin
dependent kinase inhibitors p21 and p27 responded differently to GLA, p27 expression was
increased (27 ± 7.3%) while p21 remained unchanged. The expression of p53 was increased (44 ±
16%) by GLA. Finally, the BrdU incorporation studies found a significant inhibition (32 ± 11%) of
BrdU incorporation into the tumour in vivo.
Conclusion: Overall the findings reported in the present study lend further support to the
potential of GLA as an inhibitor of glioma cell proliferation in vivo and show it has direct effects
upon cell cycle control and angiogenesis. These effects involve changes in protein expression of
VEGF, Flt1, ERK1, ERK2, MMP2, Cyclin D1, pRb, p53 and p27. Combination therapy using drugs
with other, complementary targets and GLA could lead to gains in treatment efficacy in this
notoriously difficult to treat tumour.
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Background
Gamma-linolenic acid has been proposed as an antitu-
mour therapy and has proven efficacy in several tumour
types [1,2]. Studies have used GLA for the treatment of
human gliomas although these trials were preliminary in
nature [3-5]. Studies in the C6 rat glioma model have
shown GLA inhibits cell proliferation and induces apop-
tosis and similar results have been obtained with human
glioma cells in primary culture [6-9]. GLA is known to
induce reactive oxygen species generation and cause lipid
peroxidation in tumour cells and leads to altered mito-
chondrial metabolism and ultrastructure, cytochrome c
release, caspase activation and apoptosis [10-14]. Both
GLA and its metabolic products can alter the gene expres-
sion of several proteins and GLA is known to inhibit gli-
oma cell migration [14-16].
One of the major problems of glioma progression is
intense angiogenesis which has been related not only to
tumour nutrition but also to tumour cell migration along
the basement membrane of the growing blood vessels
[17]. In gliomas, the best characterized pro-angiogenic
factor is vascular endothelial growth factor (VEGF), whose
overexpression is correlated with increasingly malignant
phenotypes [18]. VEGF and its receptors Flt1 (VEGFR1)
and Flk1 (VEGFR2) are important proteins in the ang-
iogenic process and represent a treatment target in many
tumours including gliomas. In order for angiogenesis to
progress extracellular matrix (ECM) degradation is neces-
sary and the metalloproteinases 2 and 9 (MMP2 and
MMP9) are highly expressed in gliomas [19,20]. Interest-
ingly, GLA is known to inhibit both endothelial cell pro-
liferation and induce endothelial cell apoptosis. Several
studies have reported GLA-induced changes in endothe-
lial cells including altered occludin and VE-cadherin
expression and altered barrier properties [21,22]. Polyun-
saturated fatty acids have also been reported to influence
MMP2 expression in endothelial cells [23]. However the
effects of GLA on cell cycle and angiogenesis related pro-
teins in gliomas in vivo has not been explored and is the
principal focus of the present study.
The aim of the study was to determine the effects of slow
(0.5 μl/hr) osmotic pump infusion of 5 mM GLA on fac-
tors related to the angiogenic process and to the control of
the cell cycle in the C6 rat glioma model. The mRNA and
protein expression were studied of (i) angiogenesis related
proteins: vascular endothelial growth factor (VEGF),
VEGF receptors Flt1 and Flk1, matrix metalloproteinase 2
(MMP2), matrix metalloproteinase 9 (MMP9), ERK1 and
ERK2, and (ii) cell cycle control related proteins: pRb, cyc-
lin D1, E2F1, p16, p21, p27 and p53. Immunohistochem-
ical localization of proteins was performed by light
microscopy and semi-quantitative analysis of protein
expression was performed for VEGF, Flt1 and Flk1. MMP2
proteolytic activity was determined by zymography in
order to determine GLA effects on ECM degradation
capacity in vivo. Glial fibrillary acidic protein (GFAP) was
immunohistochemically localized in order to determine
the tumour area by image analysis. Bromodeoxyuridine
(BrdU) incorporation was analysed by immunohisto-
chemical localization of the compound to determine the
effects of GLA on S-phase DNA synthesis in vivo.
Methods
Cell culture
C6 rat glioma cells were obtained from the ATCC and
stocks were maintained frozen (liquid nitrogen) in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% foetal calf serum and 20% glycerol. Stock cells
were grown in DMEM containing 10% foetal calf serum
and antibiotics (penicillin 50 U/ml, streptomycin 50 μg/
ml). Cells in the exponential phase of growth were used,
growing in 75 cm2 flasks in a humidified atmosphere of
5% CO2: 95% air at 37°C.
Surgical procedures
C6 rat glioma cells were grown in Dulbecco's modified
Eagle medium (DMEM) containing 10% foetal calf serum
and antibiotics (penicillin/streptomycin). Cells in the
exponential phase of growth were used and a suspension
prepared in sterile saline at a concentration of 5 × 105 cells
per 4–5 μl. Adult female Wistar rats of 250–350 g (n = 34)
were anaesthetised with an intramuscular injection of ket-
amine:xylazine, 10 mg:1.5 mg/100 g body weight to pro-
vide deep anaesthesia and analgesia. The rats were placed
on a stereotaxic surgical table, a midline incision was
made and a burrhole was drilled 0.48 mm anterior and 3
mm lateral to bregma. The C6 cell suspension was slowly
injected into the striatum using a Hamilton syringe at a
depth of 5.4 mm to the bone surface and the needle left in
situ for 3 minutes before its removal. After 14 days Alzet
osmotic pumps containing artificial cerebrospinal fluid
(CSF) (Alzet) or 5 mM GLA in artificial CSF were surgi-
cally implanted and attached to Alzet brain infusion kits.
Artificial CSF was chosen as a vehicle solution in order to
mimic more closely the composition of the interstitial
fluid within the brain. These concentrations were chosen
based on previous work and unpublished data from our
laboratory [7]. The pump infusion rate was 0.5 μl/hr with
a duration of 2 weeks. After a further 14 days the rats were
killed by transcardiac perfusion with 4% formaldehyde in
0.1 M phosphate buffer, pH7.4 or by anaesthetic overdose
for removal of fresh tissues for RT-PCR and western blot-
ting. This procedure was approved by the Ethical Com-
mission for Animal Experimentation of the Biomedical
Institute (University of São Paulo) – protocol number
190/02.Lipids in Health and Disease 2009, 8:8 http://www.lipidworld.com/content/8/1/8
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Antibodies
The antibodies used in this study were: MMP-2 (goat),
MMP-2 (mouse), MMP-9 (goat), MMP-9 (mouse), VEGF
(mouse), VEGF (rabbit), Flt-1 (rabbit), Flk-1 (rabbit),
cd34 (mouse), BrdU (mouse), pRb (rabbit), cyclin D1
(rabbit), E2F1 (rabbit), p16 (mouse), p21 (rabbit), p27
(rabbit), p53 (rabbit), ERK1/ERK2 (rabbit) and GFAP
(goat). All of the primary antibodies were purchased from
Santa Cruz Biotechnology, USA. Biotinylated Ulex euro-
paeus lectin was from Vector Laboratories, USA. Bioti-
nylated secondary antibodies (anti-goat, anti-mouse and
anti-rabbit) used for IHC were produced in donkey (Santa
Cruz Biotechnology, USA), and the streptavidin-biotin/
HRP (horseradish peroxidase) was produced by Amer-
sham Biosciences, UK.
Immunohistochemical (IHC) analysis
The perfused brains were cryoprotected in a solution of
20% sucrose in 0.1 M potassium phosphate buffer (KPB)
overnight. The brain sections were cut on a freezing micro-
tome (Leica SM 2000R) and mounted on gelatinized
slides. The sections were dried at 40°C-50°C for 2 hours
and were maintained at -20°C until analysis. Immunohis-
tochemical analysis followed [14] described briefly here.
The sections were incubated at room temperature over-
night with the respective primary antibody (MMP-2,
MMP-9, Flt-1 and Flk-1, 1:100, VEGF, CD34 and BrdU
1:200 and GFAP, 1:500) diluted in PBST. The negative
controls received only PBST. The slides were washed with
PBST and incubated with the secondary antibodies
(1:500–1:1000 in PBST) for 90 minutes. The slides were
washed again with PBST and incubated with streptavidin-
HRP (1:100–1:200 in PBST) for 60 minutes. The reactions
were developed with 0.04% 3,3'-diaminobenzidine
(DAB) + 0.03% H2O2. For MMP-2, Flt-1, Flk-1 and GFAP
the DAB reactions were intensified with an OsO4 solution
(0.04%) for 30 minutes. All slides were counterstained
with 0.1% methyl-green, dehydrated and mounted with
Permount® (Fisher Scientific).
mRNA expression analysis by RT-PCR
Samples were dissected with the aid of a surgical micro-
scope and used for total RNA extraction with Trizol (Life
Technologies, USA). The first strand of complementary
DNA (cDNA) was generated from 1 μg RNA as previously
described [24]. PCR amplification cycle: 1 minute at
94°C, 1 minute at primer-specific temperature and 1
minute at 72°C. To ensure the exponential phase of
amplification, the number of PCR cycles was determined
and optimized for each of the proteins. Controls for non-
specific amplification showed no bands on gel (data not
shown). Semi-quantitative gene expression data was cal-
culated by the ratio of respective gene/GAPDH density
after ethidium bromide staining. GAPDH expression
remained unchanged after GLA exposure. Primers used
were as follows (sense/antisense):
MMP-2 (500 bp):5'-TGGCAGTGCAATACCTGAAC-3',
5'-CAAGGTCCATAGCTCATCGTC-3';
MMP-9 (531 bp):5'-GAGGAATACCTGTACCGCTATG-3',
5'-CAAACCGAGTTGGAACCAC-3';
VEGF (148 bp):5'-CTGTACCTCCACCATGCCAAG-3',
5'-GGTACTCCTGGAAGATGTCCACC-3';
FLT-1 (453 bp):5'-TGGAAGGAGGCGAGGATTACAGT-
GAGA-3',
5'GGTAGATTCCAGGTGTGGCATACTCTGGTG-3';
FLK-1(445 bp):5'-GTACTCCAGCGACGAGGCAG-
GACTTTTA-3',
5'-TTTTATCCAGTTTCACAGAGGGCTCCATTG-3';
GAPDH (306 bp):5'-GTCGGTGTGAACGGATTTG-3',
5'-ACAAACATGGGGGCATCAG-3';
ERK1 (188 bp) 5'-CCTGCTGGACCGGATGTTA-3'
5'-GTCTCTTGGAAGATCAGCTC-3'
pRb (549 bp): 5'-TCTACCTCCCTTTCCCTGTTT-3',
5'-AGTCATTTTTGTGGGTGTTGG-3';
p16 (180 bp): 5'-TCTGCAGATAGACTAGCCA-3',
5'-CTCGCAGTTCGAATCTGCA-3';
p21 (200 bp): 5'-TCCGATCCTGGTGATGTCC-3',
5'-CGAACACGCTCCCAGACGT-3';
p27 (325 bp): 5'-GCAGCTTGCCCGAGTTCTAC-3',
5'-TTCTTGGGCGTCTGCTCCAC-3';
p53 (271 bp): 5'-GTGGCCTCTGTCATCTTCCG-3',
5'-CCGTCACCATCAGAGCAACG-3';
E2F1 (143 bp): 5'-ACGCTATGAAACCTCACTAAA-3',Lipids in Health and Disease 2009, 8:8 http://www.lipidworld.com/content/8/1/8
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5'-AGGACATTGGTGATGTCATA-3';
Cyclin D1 (435 bp): 5'-TGTTCGTGGCCTCTAAGATGA-3',
5'-GCTTGACTCCAGAAGGGCTT-3'.
Western blotting
20-μg sample proteins were electrophoresed through
7.5% SDS-PAGE and transferred to nitrocellulose mem-
branes (Hybond ECL membrane, Amersham Pharmacia
Biotech). Immunoblotting followed standard methods
[9] and fluorescent bands (Alexa-488 label) were visual-
ized in an image system (Molecular Dynamics Typhoon
8600 Variable Mode Imager). The secondary antibodies
conjugated with Alexa-488 (anti-goat, anti-mouse and
anti-rabbit) used were produced in donkey (Invitrogen –
Molecular Probes).
BrdU incorporation
DNA synthesis was determined in vivo by administration
of 100 mg/kg BrdU intraperitoneally 90 minutes before
transcardiac perfusion of CSF or GLA + CSF treated rats.
Immunohistochemical detection of cells containing BrdU
was performed on cryosections as described above. The
method used followed doses used in mouse studies [25].
Zymography
The activity of MMP2 and MMP9 was detected using
zymography on a 10% SDS-PAGE gel containing 1 mg/ml
gelatin. The proteolytic activity was identified as clear
bands on a blue background after Coomassie blue stain-
ing of the gel after protein separation by electrophoresis
and incubation for 20 hrs following the method of [26].
The intensity of the bands was determined by densitome-
try and the activity was attributed to MMPs as it was read-
ily inhibited by 5 mM EDTA solution during
development.
Gas Chromatography-Mass Spectrometry Analysis
Lipids were extracted and fatty acid methyl esters were
formed by the sulphuric acid/anhydrous methanol
method [27,28]. The fatty acid methyl esters were sepa-
rated on a DB-23 column [(50% cyanopropyl)methyl
polysiloxane, 0.25 μm film thickness, 0.250 mm × 60 m],
in a Shimadzu GCMS model QP5050 as described in [14].
Individual fatty acid methyl esters were identified by com-
parison with authentic standard retention times and mass
spectra.
Experimental Analyses
Immunohistochemistry images were captured and ana-
lysed using a CCD camera, an Olympus Optiphot micro-
scope and Image ProPlus software. All labelling above
background intensity was selected and a mask created for
immunolabelling area calculations on calibrated images.
Values were expressed in μm2 ± SEM and are the mean of
6–10 random areas within each tumour section for each
experimental animal, totalling 664 areas analysed for this
experiment.
The microvessel density was calculated by counting 5 ran-
dom high power fields (×40 objective) in each tumour
section for each experimental animal, totalling 145 areas
analysed for this experiment. Vessels of less than 14 μm
were considered as microvessels, following criteria from
[29].
Tumour area was estimated by two parameters the first
being area analysis after image capture of GFAP labelled
tumour sections. The second method was by calculating
the rostrocaudal extension of the tumour (length) from
the number of cryosections obtained for immunohisto-
chemical analysis multiplied by section thickness. Image
analysis was performed using Sigma Scan and Image Pro
Plus software.
The semi-quantitative analysis of RT-PCR products and
quantitative analysis of Western blots was performed
using a Molecular Dynamics Typhoon 8600 Variable
Mode Imager and ImageQuant. All data are presented as
the mean ± SEM. Statistical differences were determined
by one-way ANOVA with post-hoc Tukey's test and p < 0.05
was considered significant.
Results
The infusion of 5 mM GLA in CSF caused a significant
decrease in C6 tumour growth in comparison with CSF
alone in vivo (Figure 1A), as previously reported at lower
concentrations [7]. The average tumour area was reduced
by 75 ± 8.8% while the tumour length (rostrocaudal
extension) was reduced by 38 ± 9.7%. Tumour fatty acid
composition was also altered by GLA treatment with sig-
nificant increases in 18:3, n-6 and 22:5, n-6 content (Fig-
ure 1E).
After confirmation of the efficacy of treatment the expres-
sion of angiogenesis related proteins was examined by
mRNA and/or protein expression analysis. The mRNA and
protein expression of VEGF and its receptors Flt1 and Flk1
were compared in control CSF and 5 mM GLA treated ani-
mals. In Figure 1B, 1D the mRNA expression of VEGF was
reduced by 38 ± 5.8% in the presence of 5 mM GLA while
the protein expression was reduced by 71 ± 16%. The
mRNA expression of Flt1 was reduced by 77 ± 16% in the
presence of 5 mM GLA while the protein expression was
reduced by 57 ± 5.8% (Figure 1F, 1G). While GLA
increased the mRNA expression of Flk1 by 39 ± 12% its
protein expression was unchanged in the GLA treated
tumour (data not shown).Lipids in Health and Disease 2009, 8:8 http://www.lipidworld.com/content/8/1/8
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Effect of 14-day osmotic pump infusion of 5 mM gamma-linolenic acid (GLA) or control cerebrospinal fluid (CON = CSF) on  C6 glioma development in vivo Figure 1
Effect of 14-day osmotic pump infusion of 5 mM gamma-linolenic acid (GLA) or control cerebrospinal fluid 
(CON = CSF) on C6 glioma development in vivo. (A) Tumour size estimated by glial fibrillary acidic protein labeling and 
image analysis with ImageProPlus. Average tumour area (mm2) and length = rostral-caudal extension (mm) were plotted for 
CON (control CSF) and GLA (5 mM GLA + CSF) (n = 12), statistical significance, * = p < 0.0001. Left side of graph presents 
area (CON A and GLA A) while right side of graph presents length (CON L and GLA L). (B and F) mRNA expression of VEGF 
and Flt-1 in CON and GLA-treated tumours, with GAPDH as an internal control (n = 10), statistical significance, * = p < 0.001. 
(D and G) Immunohistochemical labeling for VEGF and Flt-1 CON and GLA-treated tumours, semi-quantitative analysis with 
ImageProPlus. (n = 9), statistical significance, * = p < 0.01 (C and E) Fatty acid composition by gas chromatography-mass spec-
trometry of CON (C) and GLA (E) treated tumours (n = 11), statistical significance, * = p < 0.0001. (H-J) Representative 
images of control (H), VEGF (I) and Flt-1 (J) immunohistochemical labeling (n = 9).
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GLA infusion was associated with a decrease in MMP2 (35
± 6.8%) mRNA expression (Figure 2A). MMP9 mRNA was
not expressed by the tumour and this was confirmed by
negative staining with MMP9 antibody on cryosections
and lack of activity in zymograms (data not shown). Due
to the heterogeneous distribution of MMP2 in the tumour
tissue immunohistochemical quantification was not pos-
sible. Zymography confirmed a significant decrease (32 ±
8.5%) in proteolytic activity of MMP2 in the presence of
GLA (Figure 2B). The presence of 5 mM GLA caused a sig-
nificant decrease in both ERK1 (27 ± 7.7%) and ERK2 (31
± 8.7%) protein expression (Figure 2C, 2E) and mRNA
expression (data not shown).
In the knowledge that 5 mM GLA caused significant
changes in mRNA expression and protein expression of
important factors involved in the angiogenic process we
further investigated these effects by measuring the micro-
vessel density of treated and control tumours. The micro-
vessel density of the GLA treated tumour was reduced by
44 ± 5.4% versus the control tumour (Figure 2G).
GLA was found to alter the expression of several proteins
involved in cell cycle control (Figure 3). pRb protein
expression was decreased (62 ± 18%) while E2F1
remained unchanged (Figure 3A, 3B). Cyclin D1 protein
expression was increased by 42 ± 12% in the presence of
GLA (Figure 3C). The cyclin dependent kinase inhibitors
p21 and p27 responded differently to GLA, p27 expres-
sion was increased (27 ± 7.3%) while p21 remained
unchanged (Figure 3D, 3E). C6 glioma cells did not
express the cyclin-dependent kinase inhibitor p16 (data
not shown) as previously reported [30]. The expression of
p53 was increased (44 ± 16%) by GLA (Figure 3F). Finally,
the BrdU incorporation studies found a significant inhibi-
tion (32 ± 11%) of BrdU incorporation into the tumour in
vivo (Figure 3G).
Discussion
Previous studies have shown that GLA is an effective
inhibitor of glioma cell proliferation both in vitro and in
vivo [6,7,14]. During in vivo studies infusion of 2 mM GLA
at 1 μl/hr for 7 days caused a marked inhibition (~50%)
of tumour growth accompanied by apoptosis [7]. This
finding stimulated our hypothesis that a longer period of
infusion at higher concentrations may be more effective.
The present study infused 5 mM GLA at 0.5 μl/hr for 14
days and the tumour area was significantly reduced (75 ±
8.8%) in comparison with the CSF treated tumours and
confirmed the efficacy of this treatment method in glio-
mas.
The presence of GLA caused inhibition of mRNA expres-
sion of VEGF, Flt1, ERK1/2 and MMP2 but not Flk1.
Immunohistochemical quantification confirmed the
decrease in VEGF and Flt1 protein expression and found a
lack of change in Flk1 protein content. ERK1 and ERK2
mRNA and protein expression was significantly
decreased. The importance of VEGF and its receptors Flt1
and Flk1, along with ERK1/2 and MMP2 in glioma angio-
genesis and the inhibitory effects of GLA on these pro-
teins' expression suggested the possibility that
angiogenesis could be modified in the GLA-treated
tumours. After counting microvessel density (MVD) in
both groups it was apparent that GLA had an inhibitory
effect on vessel number causing a 44 ± 5.4% reduction in
MVD. These interactions are summarized in the scheme
presented in Figure 3H. This in itself could be an impor-
tant mechanism of tumour growth inhibition by reducing
tumour nutrition and by reducing the potential for migra-
tion along blood vessels whose number is reduced by
treatment.
While the role of Flk1 in endothelial proliferation is well
known, the role of Flt1 is less well defined. Flt1 can be
found at both the cell membrane and in soluble form in
the extracellular matrix (ECM) where it is believed to
influence the angiogenic process [31,32]. It has been sug-
gested that Flt1 may protect VEGF from proteolytic degra-
dation by binding to it in the ECM [33]. The decrease in
Flt1 expression seen in the presence of GLA may reduce
the degree of protection of VEGF from degradation in the
ECM thereby compounding the effect of decreased VEGF
expression. An autocrine loop has been described in neu-
roblastoma involving VEGF, Flt1 and ERK1/2 [34] and
our current data suggest that GLA may interfere with this
loop leading to inhibition of tumour cell proliferation
and survival in C6 cells in vivo.
From the present study it may be suggested that the
marked reduction in Flt1 and VEGF expression caused by
GLA treatment could cause a reduction in angiogenesis as
seen by reduced MVD most likely through reduced
endothelial cell proliferation, although this was not quan-
tified directly. The decrease in ERK1 and ERK2 expression
may be involved in the decrease in VEGF and Flt1 expres-
sion in the GLA treated tumours. In addition, the decrease
in ERK1 and ERK2 expression could be directly linked to
decreased MMP2 expression and proteolytic activity in the
GLA treated tumours. Recent studies have shown that
ERK-specific inhibitors cause a decrease in the expression
of MMP2 in breast cancer brain metastases [35]. In addi-
tion, previous studies have shown that the n-3 PUFA's
20:5 and 22:6 cause decreased pERK concomitant with
decreased VEGF expression in HT29 colon cancer cells.
These n-3 PUFA's also caused a reduction in HT29 tumour
volume in vivo and the tumour microvessel density was
reduced [36]. It is possible that GLA may affect C6 glioma
cells in a similar manner although this remains to be con-
firmed.Lipids in Health and Disease 2009, 8:8 http://www.lipidworld.com/content/8/1/8
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Effect of 14-day osmotic pump infusion of 5 mM gamma-linolenic acid (GLA) or control cerebrospinal fluid (CON = CSF) on  protein expression and angiogenesis in the C6 glioma in vivo Figure 2
Effect of 14-day osmotic pump infusion of 5 mM gamma-linolenic acid (GLA) or control cerebrospinal fluid 
(CON = CSF) on protein expression and angiogenesis in the C6 glioma in vivo. (A) mRNA expression of MMP2 in 
CON and GLA-treated tumours, with GAPDH as an internal control (n = 10), statistical significance, * = p < 0.001. (B) Zymo-
graphic detection of MMP2 proteolytic activity in CON and GLA-treated tumours (n = 9), statistical significance, * = p < 0.004. 
Lanes 1–4 CON, 5–9 GLA. (C and E) Western blot of ERK1 and ERK2 protein expression, with GAPDH as an internal control 
(n = 11), statistical significance, * = p < 0.006. Lanes 1–5 CON, 6–11 GLA. (D) Representative images of MMP2 immunohisto-
chemical labeling (n = 9). (F and H) Haematoxylin and eosin stained sections of CON (F) and GLA (H) treated tumours. Note 
large number of blood vessels and tumour cells in the CON tumour in comparison with the GLA treated tumour. (G) Number 
of microvessels in CON and GLA-treated tumours (n = 9). Statistical significance, * = p < 0.001.
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Effect of 14-day osmotic pump infusion of 5 mM gamma-linolenic acid (GLA) or control cerebrospinal fluid (CON = CSF) on  cell cycle control in the C6 glioma in vivo Figure 3
Effect of 14-day osmotic pump infusion of 5 mM gamma-linolenic acid (GLA) or control cerebrospinal fluid 
(CON = CSF) on cell cycle control in the C6 glioma in vivo. (A) Western blot of pRb protein expression, statistical sig-
nificance, * = p < 0.009. (B) Western blot of E2F1 protein expression. (C) Western blot of cyclin D1 protein expression, statis-
tical significance, * = p < 0.008. (D) Western blot of p21 protein expression. (E) Western blot of p27 protein expression, 
statistical significance, * = p < 0.005. (F) Western blot of p53 protein expression, statistical significance, * = p < 0.026. For all 
Western blots GAPDH was used as an internal control and is presented below the protein bands of interest in A-F, (n = 11), 
Lanes 1–5 CON, 6–11 GLA. (G) Bromodeoxyuridine incorporation in vivo, representative image of labelled cells (n = 9), statis-
tical significance, * = p < 0.015. (H) Schematic presentation of changes found in GLA-treated tumours in comparison with con-
trol tumours and possible interactions among proteins based on current literature.
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Together with the changes in angiogenesis seen in GLA
treated tumours several important changes were found in
cell cycle control. The combination of decreased pRb in
the absence of functional p16 may cause the cell to lose
adequate control over the pRb pathway which is rein-
forced by the increase in cyclin D1 expression. Increased
p53 expression together with these changes in pRb and
cyclin D1 can significantly increase cell apoptosis [37-39].
E2F1 expression remained unchanged, in contrast to pre-
vious findings in vitro, demonstrating the potential impor-
tance of the orthotopic tumour microenvironment on cell
responses to GLA treatment [9]. The increase in p53 seen
in the GLA treated tumour did not lead to altered p21
expression which could explain why pRb was not
increased in this model. Instead GLA caused a significant
increase in another cyclin-dependent kinase inhibitor,
p27, causing a G1/S transition block and subsequently
reducing S-phase. This was confirmed by a reduction in S-
phase BrdU incorporation and was similar to the findings
reported for C6 glioma cells in vitro where 150 μM GLA
caused a 49% decrease in S-phase [8]. These interactions
are summarized in the scheme presented in Figure 3H.
Conclusion
Overall the findings reported in the present study lend fur-
ther support to the potential of GLA as an inhibitor of gli-
oma cell proliferation in vivo and show it has direct effects
upon cell cycle control and angiogenesis in this ortho-
topic model. Proteins related to angiogenesis which were
altered by GLA treatment included VEGF, Flt1, ERK1,
ERK2 and MMP2, while those related to cell cycle control
altered by GLA treatment included Cyclin D1, pRb, p53
and p27. Combination therapy using drugs with other,
complementary targets and GLA could lead to gains in
treatment efficacy in this notoriously difficult to treat
tumour.
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